ESR1 and breast cancer: The objectives of the conjugate design investigated in the current research are to produce conjugates capable of the delivery of cytotoxic agents to the ER positive breast cancer tumour cell, and to increase the selectivity of these cytotoxic agents which should result in less toxicity and increased efficacy.